Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Sep 26 - Oct 1
Contact Us today were happy to help you find exactly what you need
Neuroscience
Endocr Rev 28(1):84116 Gu W, Winters KA, Motani AS, Komorowski R, Zhang Y, Liu Q et al (2010) Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor
abstinence may be advised for those with advanced liver disease Metabolic risk factor management is essential: Optimising glycaemic control in patients with type 2 diabetes (with individualised HbA1c targets, typically 4858 mmol/mol depending on therapy and hypoglycaemia risk) Managing dyslipidaemia with statins where indicated (statins are safe in NAFLD) Controlling hypertension to target blood pressure levels Addressing obesity through structured weight management programmes Regarding pharmacological treatment , NICE currently states that: No medications are specifically licensed for treating NAFLD in the UK Pioglitazone may be considered in patients with type 2 diabetes and biopsy-proven NASH, though this is off-label use Vitamin E may be considered in adults without diabetes who have biopsy-proven NASH, after discussing risks and benefits (off-label use) For GLP-1 receptor agonists like Ozempic, NICE recognises their role in diabetes management and acknowledges emerging evidence for hepatic benefits, but does not currently recommend them specifically for NAFLD treatment outside their licensed indication
